RT Journal Article
SR Electronic
T1 Validation Study of HLA-B*13:01 as a Biomarker of Dapsone Hypersensitivity Syndrome in Leprosy Patients in Indonesia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.12.20048298
DO 10.1101/2020.04.12.20048298
A1 Krismawati, Hana
A1 Irwanto, Astrid
A1 Pongtiku, Arry
A1 Irwan, Ishak Darryl
A1 Maldan, Yustinus
A1 Sitanggang, Yuli Arisanti
A1 Wahyuni, Tri
A1 Tanjung, Ratna
A1 Sun, Yonghu
A1 Liu, Hong
A1 Zhang, Furen
A1 Oktavian, Antonius
A1 Liu, Jianjun
YR 2020
UL http://medrxiv.org/content/early/2020/04/15/2020.04.12.20048298.abstract
AB Importance Leprosy is a stigmatizing, chronic infection which degenerates the nervous system and often leads to incapacitation. Multi-drug therapy (MDT) which consists of dapsone, rifampicin and clofazimine has been effective to combat this disease. In Indonesia, leprosy is still a problem. Furthermore, there had been reports of Dapsone Hypersensitivity Syndrome (DHS) which also challenges leprosy elimination in certain aspects. HLA-B*13:01 has been found to be associated with DHS and prospective screening has proven its ability to prevent DHS in the Chinese population, but has not been validated in Indonesians.Objective To validate HLA-B*13:01 as a biomarker for DHS in the Indonesian population.Design This is a case-control study.Setting Population-based, multi-district recruitment from primary care centers in two of the top 3 most prevalent provinces in Indonesia, Papua and West Papua.Participants Leprosy patients who presented themselves with DHS were recruited as case subjects (34 cases) and leprosy patients without DHS were recruited as control subjects (52 controls).Exposure Leprosy patients who had undergone multi-drug treatment for leprosy under the standard WHO guideline, consisting of rifampicin, dapsone and clofazamine.Main Outcome and Measures The association of HLA-B*13:01 to DHS based on difference in allele frequencies between cases and controls. HLA-B alleles were typed using the gold-standard Sequence Based Typing method. Results were analyzed using logistic regression and risk assessment was carried out.Results The results of HLA-typing showed that HLA-B*13:01 was the most significant allele associated with DHS, with odds ratio=247.6 and P-value=4.81E-9, confirming the strong association of HLA-B*13:01 to DHS in the Indonesian population. The sensitivity of this biomarker is 91.2% and specificity is 96.2%, with an area under the curve of 0.95.Conclusions and Relevance HLA-B*13:01 is validated as a biomarker for DHS in leprosy patients in Indonesia, and can potentially be a good predictor of DHS to help prevent this condition in the future.Question Can HLA-B*13:01 be a predictor of Dapsone Hypersensitivity Syndrome in Indonesians?Findings In this case control validation study, HLA-B*13:01 is significantly associated with DHS in Indonesians and can predict a person at risk of DHS 95% of the time.Meaning HLA-B*13:01 is validated as a biomarker for DHS in Indonesians and can be useful to screen and prevent further incidences of DHS in the population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from the National Key Research and Development Program of China (2016YFE0201500), Genome Institute of Singapore, Agency for Science Technology and Research, and National Institute of Health Research and Development, Ministry of Health Republic of Indonesia.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated and analysed in this study has been included. Any additional data not in the paper can be provided by authors upon request.DHSdapsone hypersensitivity syndromeDNAdeoxyribonucleic acidHLAHuman Leukocyte AntigenMDTmulti-drug treatmentORodds ratio